As calcitonin gene-related peptide inhibitors continue to prove their value as important options in migraine prevention, there’s been a lot of anticipation about the promise for significantly better quality of life outcomes for patients with migraine. What can clinicians expect from this new class of monoclonal antibodies? Here, the limbic talks to leading migraine specialist ...
Targeted therapies herald new hope for migraine prevention
15 Jun 2020
Sponsored by Eli Lilly Australia Pty Ltd